FI4225753T3 - Voimakkaita ja selektiivisiä yhdisteitä serotoniini 1b -reseptorin modulaattoreina - Google Patents
Voimakkaita ja selektiivisiä yhdisteitä serotoniini 1b -reseptorin modulaattoreina Download PDFInfo
- Publication number
- FI4225753T3 FI4225753T3 FIEP21789678.6T FI21789678T FI4225753T3 FI 4225753 T3 FI4225753 T3 FI 4225753T3 FI 21789678 T FI21789678 T FI 21789678T FI 4225753 T3 FI4225753 T3 FI 4225753T3
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- dimethylamino
- ethoxy
- oxadiazol
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 17
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 title 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 26
- 229960003966 nicotinamide Drugs 0.000 claims 13
- 235000005152 nicotinamide Nutrition 0.000 claims 13
- 239000011570 nicotinamide Substances 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 6
- 239000013066 combination product Substances 0.000 claims 4
- 229940127555 combination product Drugs 0.000 claims 4
- -1 [1,1'-biphenyl]-4-carboxamide 2'-cyano-N-(5-cyano-4-(2-(dimethylamino)ethoxy)pyridin-2-yl)-4'-(5-methyl-1 ,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxamide Chemical compound 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- AKLZTLIDPGPARM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 AKLZTLIDPGPARM-UHFFFAOYSA-N 0.000 claims 1
- QJBIDOKVAKPOCN-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 QJBIDOKVAKPOCN-UHFFFAOYSA-N 0.000 claims 1
- DLQPALGVQHBTNN-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 DLQPALGVQHBTNN-UHFFFAOYSA-N 0.000 claims 1
- HYXPMSNQGXPFDG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HYXPMSNQGXPFDG-UHFFFAOYSA-N 0.000 claims 1
- XEXBGLIFZLBHJQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 XEXBGLIFZLBHJQ-UHFFFAOYSA-N 0.000 claims 1
- ARTHJZBQVIILKI-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 ARTHJZBQVIILKI-UHFFFAOYSA-N 0.000 claims 1
- VSKSGHUYVPALCB-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 VSKSGHUYVPALCB-UHFFFAOYSA-N 0.000 claims 1
- HNZMGCCCOSRCSD-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HNZMGCCCOSRCSD-UHFFFAOYSA-N 0.000 claims 1
- YKEMKZJDHOXQNC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 YKEMKZJDHOXQNC-UHFFFAOYSA-N 0.000 claims 1
- CWDGORUDBCIMMR-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 CWDGORUDBCIMMR-UHFFFAOYSA-N 0.000 claims 1
- NKAZJDQVTVOZIE-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 NKAZJDQVTVOZIE-UHFFFAOYSA-N 0.000 claims 1
- HVTSQRXEZRBMJU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HVTSQRXEZRBMJU-UHFFFAOYSA-N 0.000 claims 1
- TXEWRHMDULAEOH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 TXEWRHMDULAEOH-UHFFFAOYSA-N 0.000 claims 1
- HGYLTZHADHYQNA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 HGYLTZHADHYQNA-UHFFFAOYSA-N 0.000 claims 1
- VSOMIPBUJQCXGL-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 VSOMIPBUJQCXGL-UHFFFAOYSA-N 0.000 claims 1
- QNUWHCPAJAJDOA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QNUWHCPAJAJDOA-UHFFFAOYSA-N 0.000 claims 1
- WKRMNNWLWBWNLA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 WKRMNNWLWBWNLA-UHFFFAOYSA-N 0.000 claims 1
- PJFQHYDSGISEIW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 PJFQHYDSGISEIW-UHFFFAOYSA-N 0.000 claims 1
- IDMJYSVBSMXIDI-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 IDMJYSVBSMXIDI-UHFFFAOYSA-N 0.000 claims 1
- GPWJQOWHTBGDNK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 GPWJQOWHTBGDNK-UHFFFAOYSA-N 0.000 claims 1
- DMBQZOISSRPCIC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 DMBQZOISSRPCIC-UHFFFAOYSA-N 0.000 claims 1
- MDFDNENUWXMCFV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 MDFDNENUWXMCFV-UHFFFAOYSA-N 0.000 claims 1
- RHAPZGCORGTSST-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 RHAPZGCORGTSST-UHFFFAOYSA-N 0.000 claims 1
- NEYFLJXXSDPBCH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 NEYFLJXXSDPBCH-UHFFFAOYSA-N 0.000 claims 1
- QLSOTVJXMCZKEB-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QLSOTVJXMCZKEB-UHFFFAOYSA-N 0.000 claims 1
- XCQDOZFRSBWIGG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 XCQDOZFRSBWIGG-UHFFFAOYSA-N 0.000 claims 1
- KCWVWVUHPWLROW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 KCWVWVUHPWLROW-UHFFFAOYSA-N 0.000 claims 1
- RNORLAMEMJTVPV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 RNORLAMEMJTVPV-UHFFFAOYSA-N 0.000 claims 1
- JLZHEEGMMGGWRU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 JLZHEEGMMGGWRU-UHFFFAOYSA-N 0.000 claims 1
- TXTMHWUUHFAVQW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 TXTMHWUUHFAVQW-UHFFFAOYSA-N 0.000 claims 1
- GOLFEXPALIXFKJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 GOLFEXPALIXFKJ-UHFFFAOYSA-N 0.000 claims 1
- QVWABOCPMMJQAV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QVWABOCPMMJQAV-UHFFFAOYSA-N 0.000 claims 1
- UCQLYQBGXGOQCG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 UCQLYQBGXGOQCG-UHFFFAOYSA-N 0.000 claims 1
- NDGORFKNJAVUQY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 NDGORFKNJAVUQY-UHFFFAOYSA-N 0.000 claims 1
- GIULCICYOABOEC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 GIULCICYOABOEC-UHFFFAOYSA-N 0.000 claims 1
- FVWHKKVWTBOKBV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 FVWHKKVWTBOKBV-UHFFFAOYSA-N 0.000 claims 1
- ILAOTZUJBKKNCV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 ILAOTZUJBKKNCV-UHFFFAOYSA-N 0.000 claims 1
- IYMMRMDCBUSLDQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 IYMMRMDCBUSLDQ-UHFFFAOYSA-N 0.000 claims 1
- BVFPGEQMCOESHQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 BVFPGEQMCOESHQ-UHFFFAOYSA-N 0.000 claims 1
- DTVDYOBOXNJMPK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 DTVDYOBOXNJMPK-UHFFFAOYSA-N 0.000 claims 1
- ZKHDTUWYLCRTGZ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 ZKHDTUWYLCRTGZ-UHFFFAOYSA-N 0.000 claims 1
- UMQJRNKSLUJLDJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 UMQJRNKSLUJLDJ-UHFFFAOYSA-N 0.000 claims 1
- XHPASMPECUATQY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 XHPASMPECUATQY-UHFFFAOYSA-N 0.000 claims 1
- YSAMJBGGJXUMKQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 YSAMJBGGJXUMKQ-UHFFFAOYSA-N 0.000 claims 1
- UUDUCQTYLISIAL-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 UUDUCQTYLISIAL-UHFFFAOYSA-N 0.000 claims 1
- HUCZYPBVTPYVIX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HUCZYPBVTPYVIX-UHFFFAOYSA-N 0.000 claims 1
- SASAFFCTHHUDNM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 SASAFFCTHHUDNM-UHFFFAOYSA-N 0.000 claims 1
- HYCLRLSNZCRQFK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HYCLRLSNZCRQFK-UHFFFAOYSA-N 0.000 claims 1
- USUHEGLDPFIFEX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 USUHEGLDPFIFEX-UHFFFAOYSA-N 0.000 claims 1
- OPNRWYVUOUFNTF-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 OPNRWYVUOUFNTF-UHFFFAOYSA-N 0.000 claims 1
- PVISRTSBCRPJAU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 PVISRTSBCRPJAU-UHFFFAOYSA-N 0.000 claims 1
- LZASDPRDDDIIBM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 LZASDPRDDDIIBM-UHFFFAOYSA-N 0.000 claims 1
- 102100038520 Calcitonin receptor Human genes 0.000 claims 1
- 101710178048 Calcitonin receptor Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims 1
- 229960000801 nelarabine Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382888 | 2020-10-08 | ||
| PCT/EP2021/077660 WO2022074103A1 (en) | 2020-10-08 | 2021-10-07 | Potent and selctive compounds as serotonin 1b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4225753T3 true FI4225753T3 (fi) | 2024-08-29 |
Family
ID=73030029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21789678.6T FI4225753T3 (fi) | 2020-10-08 | 2021-10-07 | Voimakkaita ja selektiivisiä yhdisteitä serotoniini 1b -reseptorin modulaattoreina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12540133B2 (enExample) |
| EP (2) | EP4225753B1 (enExample) |
| JP (1) | JP7687636B2 (enExample) |
| KR (1) | KR20230107566A (enExample) |
| CN (1) | CN116635390B (enExample) |
| AU (1) | AU2021356114A1 (enExample) |
| CA (1) | CA3194700A1 (enExample) |
| CL (1) | CL2023001021A1 (enExample) |
| DK (1) | DK4225753T3 (enExample) |
| ES (1) | ES2985416T3 (enExample) |
| FI (1) | FI4225753T3 (enExample) |
| HR (1) | HRP20241184T1 (enExample) |
| HU (1) | HUE068199T2 (enExample) |
| IL (1) | IL301806B2 (enExample) |
| LT (1) | LT4225753T (enExample) |
| MX (1) | MX2023004116A (enExample) |
| PL (1) | PL4225753T3 (enExample) |
| PT (1) | PT4225753T (enExample) |
| RS (1) | RS65956B1 (enExample) |
| SI (1) | SI4225753T1 (enExample) |
| WO (1) | WO2022074103A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102993831B1 (ko) | 2020-10-08 | 2026-07-23 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조 |
| CN117903116A (zh) * | 2021-08-27 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 细胞周期蛋白k降解剂 |
| JP2026521568A (ja) | 2023-06-16 | 2026-06-30 | レウコス バイオテク ソシエダッド リミターダ | ５－ｈｔｒ１ｂ調節因子を用いた固形腫瘍の治療 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW240217B (enExample) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
| US5801170A (en) | 1993-12-07 | 1998-09-01 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5HT1D antagonists |
| ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
| SK492001A3 (en) | 1998-07-20 | 2001-08-06 | Merck Patent Gmbh | Biphenyl derivatives |
| HUP0302966A2 (hu) | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| WO2007057742A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Novel piperazinone derivatives |
| WO2007077457A2 (en) | 2006-01-06 | 2007-07-12 | The Royal Veterinary College | Treatment of equine laminitis with 5-ht1b/ 1d antagonists |
| EP3348266A1 (en) | 2017-01-16 | 2018-07-18 | Leukos Biotech, S.L. | Combination therapy for treating cancer |
-
2021
- 2021-10-07 EP EP21789678.6A patent/EP4225753B1/en active Active
- 2021-10-07 JP JP2023522401A patent/JP7687636B2/ja active Active
- 2021-10-07 WO PCT/EP2021/077660 patent/WO2022074103A1/en not_active Ceased
- 2021-10-07 US US18/248,393 patent/US12540133B2/en active Active
- 2021-10-07 RS RS20240938A patent/RS65956B1/sr unknown
- 2021-10-07 LT LTEPPCT/EP2021/077660T patent/LT4225753T/lt unknown
- 2021-10-07 DK DK21789678.6T patent/DK4225753T3/da active
- 2021-10-07 KR KR1020237015543A patent/KR20230107566A/ko active Pending
- 2021-10-07 CA CA3194700A patent/CA3194700A1/en active Pending
- 2021-10-07 PT PT217896786T patent/PT4225753T/pt unknown
- 2021-10-07 EP EP24191411.8A patent/EP4445901A3/en not_active Withdrawn
- 2021-10-07 ES ES21789678T patent/ES2985416T3/es active Active
- 2021-10-07 FI FIEP21789678.6T patent/FI4225753T3/fi active
- 2021-10-07 SI SI202130183T patent/SI4225753T1/sl unknown
- 2021-10-07 PL PL21789678.6T patent/PL4225753T3/pl unknown
- 2021-10-07 CN CN202180068969.0A patent/CN116635390B/zh active Active
- 2021-10-07 HU HUE21789678A patent/HUE068199T2/hu unknown
- 2021-10-07 IL IL301806A patent/IL301806B2/en unknown
- 2021-10-07 MX MX2023004116A patent/MX2023004116A/es unknown
- 2021-10-07 AU AU2021356114A patent/AU2021356114A1/en active Pending
- 2021-10-07 HR HRP20241184TT patent/HRP20241184T1/hr unknown
-
2023
- 2023-04-06 CL CL2023001021A patent/CL2023001021A1/es unknown
-
2026
- 2026-01-15 US US19/450,120 patent/US20260138974A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260138974A1 (en) | 2026-05-21 |
| US20240166639A1 (en) | 2024-05-23 |
| WO2022074103A1 (en) | 2022-04-14 |
| KR20230107566A (ko) | 2023-07-17 |
| CL2023001021A1 (es) | 2023-11-24 |
| DK4225753T3 (da) | 2024-08-19 |
| CN116635390A (zh) | 2023-08-22 |
| CN116635390B (zh) | 2026-03-27 |
| ES2985416T3 (es) | 2024-11-05 |
| CA3194700A1 (en) | 2022-04-14 |
| JP7687636B2 (ja) | 2025-06-03 |
| LT4225753T (lt) | 2024-08-26 |
| IL301806B1 (en) | 2026-01-01 |
| US12540133B2 (en) | 2026-02-03 |
| EP4445901A3 (en) | 2024-12-04 |
| PT4225753T (pt) | 2024-08-30 |
| HRP20241184T1 (hr) | 2024-11-22 |
| EP4445901A2 (en) | 2024-10-16 |
| SI4225753T1 (sl) | 2024-10-30 |
| EP4225753A1 (en) | 2023-08-16 |
| IL301806A (en) | 2023-05-01 |
| AU2021356114A9 (en) | 2024-09-12 |
| IL301806B2 (en) | 2026-05-01 |
| PL4225753T3 (pl) | 2024-11-18 |
| EP4225753B1 (en) | 2024-07-31 |
| JP2023547346A (ja) | 2023-11-10 |
| HUE068199T2 (hu) | 2024-12-28 |
| AU2021356114A1 (en) | 2023-05-18 |
| RS65956B1 (sr) | 2024-10-31 |
| MX2023004116A (es) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019301628C1 (en) | Pyridine carboxamide compounds for inhibiting NaV1.8 | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| AU2015335694B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP4294960B2 (ja) | 抗癌剤としてのサイクリン依存性キナーゼ阻害剤 | |
| KR101958501B1 (ko) | 설폭시민기 함유 4-아릴-ｎ-페닐-1,3,5-트리아진-2-아민 | |
| CN100355751C (zh) | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 | |
| AU2007336781C1 (en) | Pyridazinones and furan-containing compounds | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| TW201920081A (zh) | 作為鈉通道調節劑的羧醯胺 | |
| EP4323350A1 (en) | Isoindolinone compounds | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| BR122017003188A2 (pt) | composto 1-{2-[4-(2-amino-5-cloro-3-piridinil)fenóxi]-5-pirimidinil}-3-[2-(metilsulfonil)-5-(trifluorometil)fenil]ureia, sal deste, composição farmacêutica compreendendo-os e uso destes para o tratamento de câncer | |
| KR20160030275A (ko) | 암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물 | |
| CN104822373A (zh) | 治疗性化合物和组合物 | |
| IL276575B1 (en) | Inhibitors of btk and mutants thereof | |
| KR20140117684A (ko) | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 | |
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2023547346A5 (enExample) | ||
| HRP20241184T1 (hr) | Moćni i selektivni spojevi kao modulatori serotonin 1b receptora | |
| JP2026506844A (ja) | Ａｋｔ１の共有結合改質剤およびその使用 | |
| EP1802606A2 (en) | Compositions and their use as anti-tumor agents | |
| JP2021514399A5 (enExample) | ||
| IL296632A (en) | phd inhibitory compounds, compositions and use | |
| CN110437220B (zh) | 三氮唑类化合物及其应用 |